LOS ANGELES, March 11, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against GSK plc.

You can also reach us through the firm's website at www.schallfirm.com ... According to the Complaint, the Company made false and misleading statements to the market. GSK claims to investors that its ...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirmed ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

seeking to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on the Law360.com website. GSK's vaccine has just hit the mark in a phase 3 trial, and the company is ...

CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

In trading on Tuesday, shares of GSK plc (Symbol: GSK) crossed above their 200 day moving average of $38.45, changing hands as high as $39.19 per share. GSK plc shares are currently trading up ...